OKYO Pharma to Start Phase 2 Trial for Neuropathic Corneal Pain
Ticker: OKYO · Form: 6-K · Filed: Jul 11, 2024 · CIK: 1849296
| Field | Detail |
|---|---|
| Company | Okyo Pharma LTD (OKYO) |
| Form Type | 6-K |
| Filed Date | Jul 11, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial, ophthalmology, drug-development
TL;DR
OKYO Pharma kicking off Phase 2 trial for OK-101 in Q3 2024 for corneal pain.
AI Summary
OKYO Pharma Ltd announced on July 11, 2024, its intention to initiate a Phase 2 clinical trial for its drug candidate OK-101 to treat neuropathic corneal pain. The trial is slated to commence in the third quarter of 2024 and will be a one-year study, building upon positive pre-clinical animal model data.
Why It Matters
This advancement into Phase 2 trials is a critical step for OKYO Pharma, potentially validating OK-101 as a treatment for neuropathic corneal pain and impacting future drug development in ophthalmology.
Risk Assessment
Risk Level: medium — Advancing to Phase 2 trials carries inherent risks related to clinical efficacy, patient recruitment, and regulatory approval, which can significantly impact the company's valuation.
Key Numbers
- Phase 2 — Clinical Trial Phase (Indicates progression in drug development)
Key Players & Entities
- OKYO Pharma LTD (company) — Registrant
- OK-101 (drug_candidate) — Drug being tested
- July 11, 2024 (date) — Announcement date
- Q3 2024 (date) — Expected trial start date
FAQ
What is the primary indication for the OK-101 Phase 2 clinical trial?
The Phase 2 clinical trial for OK-101 is focused on treating neuropathic corneal pain.
When is the OK-101 Phase 2 clinical trial expected to begin?
The trial is expected to begin in the third quarter of 2024 (Q3 2024).
What type of data supports the advancement of OK-101 into Phase 2 trials?
The advancement is supported by pre-clinical animal model data.
What is the duration of the planned Phase 2 study for OK-101?
The study is planned to be a one-year study.
What is the filing date of this Form 6-K report?
This Form 6-K report was filed on July 11, 2024.
Filing Stats: 365 words · 1 min read · ~1 pages · Grade level 14.7 · Accepted 2024-07-11 07:00:09
Filing Documents
- form6-k.htm (6-K) — 23KB
- ex99-1.htm (EX-99.1) — 24KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001493152-24-026886.txt ( ) — 57KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: July 11, 2024 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 News Announcement, dated July 11, 2024 4